[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586547":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":52,"centralContacts":57,"locations":62,"responsibleParty":74,"collaborators":38,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":38,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":38,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":38,"overallStatus":95,"whyStopped":38,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Chong Kun Dang Pharmaceutical","INDUSTRY",[8,15,20,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Test Group1","EXPERIMENTAL","CKD-843 dose#1 + Placebo of Dutasteride Capsule",[13,14],"Drug: CKD-843 dose#1","Drug: Placebo of Dutasteride Capsule",{"label":16,"type":10,"description":17,"interventionNames":18},"Test Group2","CKD-843 dose#2 + Placebo of Dutasteride Capsule",[19,14],"Drug: CKD-843 dose#2",{"label":21,"type":22,"description":23,"interventionNames":24},"Placebo-controlled Group","PLACEBO_COMPARATOR","Placebo of CKD-843 dose + Placebo of Dutasteride Capsule",[25,14],"Drug: Placebo of CKD-843 dose",{"label":27,"type":28,"description":29,"interventionNames":30},"Active-controlled Group","ACTIVE_COMPARATOR","Placebo of CKD-843 dose + Dutasteride Capsules",[25,31],"Drug: Dutasteride Capsules",[33,39,42,45,49],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","CKD-843 dose#1","IM injection every 3 months for 12 months",[9],null,{"type":34,"name":40,"description":36,"armGroupLabels":41,"otherNames":38},"CKD-843 dose#2",[16],{"type":34,"name":43,"description":36,"armGroupLabels":44,"otherNames":38},"Placebo of CKD-843 dose",[27,21],{"type":34,"name":46,"description":47,"armGroupLabels":48,"otherNames":38},"Dutasteride Capsules","oral, once daily, 12 months",[27],{"type":34,"name":50,"description":47,"armGroupLabels":51,"otherNames":38},"Placebo of Dutasteride Capsule",[21,9,16],[53],{"name":54,"affiliation":55,"role":56},"OhSang Kwon, MD, PhD","Seoul National University Hospital","PRINCIPAL_INVESTIGATOR",[58],{"name":54,"role":59,"phone":60,"phoneExt":38,"email":61},"CONTACT","+2-2072-2417","oskwon@snu.ac.kr",[63],{"facility":55,"status":38,"city":64,"state":38,"zip":38,"country":65,"countryCode":38,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Seoul","South Korea",{"type":67,"coordinates":68},"Point",[69,70],126.9784,37.566,{"lat":70,"lon":69},[73],{"name":54,"role":59,"phone":60,"phoneExt":38,"email":61},{"type":75,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100586547","phase-3-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-ckd-843-in-male-patients-with-androgenetic-alopecia-100586547",false,"NCT06916793","A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia","A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia","Key Inclusion Criteria:\n\n* Male of age 18-50 years\n* Clinical Diagnosis of Androgenetic Alopecia\n* Written informed consent\n\nKey Exclusion Criteria:\n\n* Other types of Alopecia or other diseases that can cause hair loss\n* Clinically significant scalp disease such as seborrheic dermatitis or psoriasis\n* Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator\n* Participants who do not agree to use contraception during the trial and for 24 weeks after the last dose, and plan to provide sperm or conceive within 24 weeks after the last dose","MALE","18 Years","50 Years",{"count":87,"type":88},288,"ESTIMATED","INTERVENTIONAL",[91],"PHASE3","This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia",[94],"Androgenetic Alopecia","NOT_YET_RECRUITING","2025-04-01",{"date":98,"type":99},"2025-04-08","ACTUAL",{"date":101,"type":88},"2025-04-30",{"date":103,"type":88},"2027-09-17",{"name":5,"class":6},1]